A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003396/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
提供机构：
Vivli
创建时间：
2019-04-12
